AngioDynamics, Inc. (OQ:ANGO)

Business Focus: Medical Equipment, Supplies & Distribution

Apr 04, 2024 07:00 am ET

AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture

AngioDynamics, Inc. (NASDAQ: ANGO):

Apr 04, 2024 06:45 am ET

AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the United States Food and Drug Administration (FDA) has cleared the AlphaVac F1885 System for the treatment of pulmonary embolism (PE), enhancing its utility in critical medical scenarios such as PE.

Apr 01, 2024 05:26 pm ET

AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it has entered into a settlement agreement with Becton, Dickinson and Company (“BD”) to resolve all outstanding patent litigation with C.R. Bard, Inc., an affiliate of BD.

Mar 19, 2024 04:01 pm ET

AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market open on Thursday, April 4, 2024. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Mar 06, 2024 04:01 pm ET

AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 34th Annual Virtual Healthcare MedTech & Services Conference at 12:40 p.m. ET on Tuesday, March 12, 2024.

Feb 15, 2024 04:05 pm ET

AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it has completed the sale of its PICC and Midline product portfolios to Spectrum Vascular, an innovative medical device company focused on vascular access and medication management, for up to $45 million in cash.

Jan 23, 2024 08:00 am ET

AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the United States Food and Drug Administration (FDA) has cleared the Auryon XL Catheter, a 225-cm radial access catheter, for use with the Auryon Atherectomy System in the treatment of Peripheral Arterial Disease (PAD).

Jan 05, 2024 07:00 am ET

AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2024, which ended November 30, 2023.

Dec 21, 2023 04:01 pm ET

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the J.P. Morgan 42nd Annual Healthcare Conference at 9:00 a.m. PT (12:00 p.m. ET) on Thursday, January 11, 2024 in San Francisco, CA.

Dec 07, 2023 04:01 pm ET

AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the second quarter of fiscal year 2024 before the market open on Friday, January 5, 2024. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Dec 07, 2023 08:00 am ET

AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). APEX-AV is a clinical study aimed at evaluating the safety and efficacy of the Company’s AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System in the treatment of acute intermediate-risk pulmonary embolism

Oct 04, 2023 07:00 am ET

AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2024, which ended August 31, 2023.

Sep 12, 2023 04:01 pm ET

AngioDynamics to Report Fiscal 2024 First Quarter Financial Results on October 4, 2023

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the first quarter of fiscal year 2024 before the market open on Wednesday, October 4, 2023. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Aug 15, 2023 04:01 pm ET

AngioDynamics Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the Company’s AngioVac System for the proposed indications for use to include the non-surgical removal of vegetation from the right heart.

Aug 03, 2023 08:00 am ET

AngioDynamics Completes Enrollment for PRESERVE Clinical Study

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced the completion of enrollment and final treatment in its Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population (PRESERVE).

Jul 31, 2023 04:01 pm ET

AngioDynamics to Participate in a Fireside Chat at the Canaccord Genuity Growth Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference at 8:00 a.m. ET on Wednesday, August 9, 2023.

Jul 24, 2023 04:01 pm ET

AngioDynamics Announces Addition of Lorinda Burgess to Board of Directors

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of Lorinda Burgess to the Company’s Board of Directors.

Jul 12, 2023 07:00 am ET

AngioDynamics Reports Fiscal Year 2023 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2024 Guidance

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2023, which ended May 31, 2023.

Jun 20, 2023 04:01 pm ET

AngioDynamics to Report Fiscal 2023 Fourth Quarter and Full-Year Financial Results on July 12, 2023

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the fourth quarter and fiscal year 2023 before the market open on Wednesday, July 12, 2023. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Jun 08, 2023 04:01 pm ET

AngioDynamics Announces Sale of Dialysis Product Portfolio and BioSentry Product to Merit Medical Systems for $100 Million

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it has completed the sale of its Dialysis product portfolio and BioSentry Tract Sealant System Biopsy product to Merit Medical Systems, Inc. for $100 million in cash.

Apr 11, 2023 04:01 pm ET

AngioDynamics to Present at the Needham Virtual Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Needham 22nd Annual Virtual Healthcare Conference at 8:00 a.m. ET on Monday, April 17, 2023.

Mar 30, 2023 07:00 am ET

AngioDynamics Reports Fiscal 2023 Third Quarter Financial Results; Revises Guidance

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2023, which ended February 28, 2023.

Mar 13, 2023 04:01 pm ET

AngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the third quarter of fiscal year 2023 before the market open on Thursday, March 30, 2023. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Feb 28, 2023 08:00 am ET

AngioDynamics to Participate in Three Investor Conferences in March

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in the following three investor conferences in March:

Jan 05, 2023 07:00 am ET

AngioDynamics Reports Fiscal 2023 Second Quarter Financial Results; Reaffirms Guidance

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2023, which ended November 30, 2022.

Dec 20, 2022 04:01 pm ET

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the J.P. Morgan 41st Annual Healthcare Conference at 8:15 a.m. PT (11:15 a.m. ET) on Thursday, January 12, 2023 in San Francisco, CA.

Dec 15, 2022 04:01 pm ET

AngioDynamics to Report Fiscal 2023 Second Quarter Financial Results on January 5, 2023

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the second quarter of fiscal year 2023 before the market open on Thursday, January 5, 2023. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Nov 17, 2022 04:01 pm ET

AngioDynamics to Present at the Piper Sandler Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Piper Sandler 34th Annual Healthcare Conference at 10:10 a.m. ET on Wednesday, November 30, 2022.

Oct 31, 2022 04:01 pm ET

AngioDynamics Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F1885 PE System in Treatment of Pulmonary Embolism

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the enrollment of the first patient in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV), a clinical study aimed at evaluating the efficacy and safety of the Company’s AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System in the treatment of acute intermediate-risk pulmonary embolism (PE).

Oct 06, 2022 07:00 am ET

AngioDynamics Reports Fiscal 2023 First Quarter Financial Results; Reaffirms Guidance

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2023, which ended August 31, 2022.

Sep 08, 2022 04:01 pm ET

AngioDynamics to Report Fiscal 2023 First Quarter Financial Results on October 6, 2022

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that it will report financial results for the first quarter of fiscal year 2023 before the market open on Thursday, October 6, 2022. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Aug 03, 2022 04:01 pm ET

AngioDynamics to Present at the Canaccord Genuity Growth Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference at 2:00 p.m. ET on Wednesday, August 10, 2022.

Jul 12, 2022 07:00 am ET

AngioDynamics Reports Fiscal Year 2022 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2023 Guidance

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2022, which ended May 31, 2022.

Jun 15, 2022 04:01 pm ET

AngioDynamics to Report Fiscal 2022 Fourth Quarter and Full-Year Financial Results on July 12, 2022

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that it will report financial results for the fourth quarter and fiscal year 2022 before the market open on Tuesday, July 12, 2022. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

May 16, 2022 04:01 pm ET

AngioDynamics to Present at the UBS Global Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the UBS Global Healthcare Conference at 4:15 p.m. ET on Monday, May 23, 2022.

May 03, 2022 04:01 pm ET

AngioDynamics to Present at the BofA Securities Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the BofA Securities Healthcare Conference at 10:00 a.m. PT (1:00 p.m. ET) on Tuesday, May 10, 2022.

Apr 07, 2022 07:00 am ET

AngioDynamics Reports Fiscal 2022 Third Quarter Financial Results; Reaffirms Fiscal Year 2022 Guidance

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2022, which ended February 28, 2022.

Apr 04, 2022 04:01 pm ET

AngioDynamics to Present at the Needham Virtual Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 21st Annual Needham Virtual Healthcare Conference at 2:15 p.m. ET on Monday, April 11, 2022.

Mar 14, 2022 04:01 pm ET

AngioDynamics to Report Fiscal 2022 Third Quarter Financial Results on April 7, 2022

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the third quarter of fiscal year 2022 before the market open on Thursday, April 7, 2022. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Mar 08, 2022 04:01 pm ET

AngioDynamics to Present at Three Investor Conferences in March

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the following three investor conferences in March:

Feb 08, 2022 04:01 pm ET

AngioDynamics to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference at 10:00 a.m. ET on Tuesday, February 15, 2022.

Jan 06, 2022 07:00 am ET

AngioDynamics Reports Fiscal 2022 Second Quarter Financial Results; Reaffirms Revenue Guidance; Revises Gross Margin and Adjusted EPS Guidance

Jan 03, 2022 04:01 pm ET

AngioDynamics to Present at the Needham Virtual Growth Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 24th Annual Needham Virtual Growth Conference at 2:00 p.m. ET on Monday, January 10, 2022.

Dec 15, 2021 04:01 pm ET

AngioDynamics to Report Fiscal 2022 Second Quarter Financial Results on January 6, 2022

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the second quarter of fiscal year 2022 before the market open on Thursday, January 6, 2022. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Sep 30, 2021 07:00 am ET

AngioDynamics Reports Fiscal 2022 First Quarter Financial Results; Updates Guidance

Sep 15, 2021 04:01 pm ET

AngioDynamics to Report Fiscal 2022 First Quarter Financial Results on September 30, 2021

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of fiscal year 2022 before the market open on Thursday, September 30, 2021. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Jul 29, 2021 04:01 pm ET

AngioDynamics to Present at the Canaccord Genuity Virtual Growth Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 41st Annual Canaccord Genuity Virtual Growth Conference at 9:00 a.m. ET on Wednesday, August 11, 2021.

Jul 13, 2021 07:00 am ET

AngioDynamics Reports Fiscal 2021 Fourth Quarter and Full-Year Financial Results

Jul 08, 2021 06:30 pm ET

AngioDynamics Announces Details for Investor & Technology Day on July 13, 2021

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will host its Investor & Technology Day on Tuesday, July 13, from 9:30 a.m. to approximately 11:30 a.m. ET, which will include a question-and-answer session.

Jun 24, 2021 04:01 pm ET

AngioDynamics to Report Fiscal 2021 Fourth Quarter and Full-Year Financial Results and Host Investor & Technology Day on July 13, 2021

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the fourth quarter and fiscal year 2021 before the market open on Tuesday, July 13, 2021. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Jun 08, 2021 07:00 am ET

AngioDynamics Receives 510(k) Clearance for AlphaVac Mechanical Thrombectomy System

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the AlphaVac Mechanical Thrombectomy System, an off-circuit, multi-purpose mechanical aspiration thrombectomy device for the non-surgical removal of thrombi or emboli from the vasculature.

Jun 01, 2021 04:01 pm ET

AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors

AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced...

May 17, 2021 04:01 pm ET

AngioDynamics to Present at the UBS Virtual Global Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will present at the UBS Virtual Global Healthcare Conference at 12:00 p.m. ET on Tuesday, May 25, 2021.

Apr 12, 2021 06:00 am ET

AngioDynamics Submits 510(k) Application to FDA for AlphaVac Mechanical Thrombectomy System

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology today announced that on April 9, 2021, it submitted a 510(k) application to the United States Food and Drug Administration (FDA) for the AlphaVac System, an off-circuit, multi-purpose mechanical aspiration thrombectomy device for the treatment of undesirable intravascular material in the venous system and peripheral vasculature.

Apr 05, 2021 04:01 pm ET

AngioDynamics to Present at the Needham Virtual Healthcare Conference

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Needham Virtual Healthcare Conference at 8:45 a.m. ET on Monday, April 12, 2021.

Mar 30, 2021 07:00 am ET

AngioDynamics Reports Fiscal 2021 Third Quarter Financial Results and Updates Guidance

Mar 15, 2021 04:01 pm ET

AngioDynamics to Participate in a Virtual Fireside Chat at the KeyBanc Life Sciences & MedTech Investor Forum

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum at 10:00 a.m. ET on Wednesday, March 24, 2021.

Mar 09, 2021 04:01 pm ET

AngioDynamics to Participate in a Virtual Fireside Chat at the Oppenheimer Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the 31st Annual Oppenheimer Healthcare Conference at 9:20 a.m. ET on Tuesday, March 16, 2021.

Mar 09, 2021 08:00 am ET

AngioDynamics to Report Fiscal 2021 Third Quarter Financial Results on March 30, 2021

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the third quarter of fiscal year 2021 before the market open on Tuesday, March 30, 2021. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Mar 01, 2021 04:01 pm ET

AngioDynamics to Present at the Barclays Virtual Global Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Barclays Virtual Global Healthcare Conference at 8:00 a.m. ET on Tuesday, March 9, 2021.

Feb 01, 2021 08:00 am ET

AngioDynamics Appoints Richard C. Rosenzweig Senior Vice President, General Counsel and Secretary, Promotes Juan Carlos Serna to Senior Vice President, Scientific & Clinical Affairs

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has appointed Richard C. Rosenzweig as Senior Vice President, General Counsel, effective January 31, 2021. Mr. Rosenzweig will also serve as Corporate Secretary to the AngioDynamics Board of Directors.

Jan 07, 2021 07:00 am ET

AngioDynamics Reports Fiscal 2021 Second Quarter Financial Results

Jan 04, 2021 04:01 pm ET

AngioDynamics to Present at the J.P. Morgan Virtual Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference at 2:50 p.m. ET on Thursday, January 14, 2021.

Dec 29, 2020 04:01 pm ET

AngioDynamics to Present at the Needham Virtual Growth Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 23rd Annual Needham Virtual Growth Conference at 1:15 p.m. ET on Monday, January 11, 2021.

Dec 09, 2020 04:01 pm ET

AngioDynamics to Report Fiscal 2021 Second Quarter Financial Results on January 7, 2021

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the second quarter of fiscal year 2021 before the market open on Thursday, January 7, 2021. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Nov 12, 2020 09:00 am ET

AngioDynamics Announces Presentation of Positive Safety, Efficacy Results from RAPID Outcomes Database

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, announced the safety and efficacy results from the Registry of AngioVac* System Procedures In Detail (RAPID) database. Results were shared by principal investigator John Moriarty, MD, FSIR, FSVM (Associate Professor of Radiology and Medicine, Cardiology—UCLA Interventional Radiology, David Geffen School of Medicine at UCLA), at the Vascular Interventional Advances (VIVA) 2020 meeting.

Sep 29, 2020 07:00 am ET

AngioDynamics Reports Fiscal 2021 First Quarter Financial Results

Sep 21, 2020 08:00 am ET

AngioDynamics Announces Commercial Launch of Auryon Atherectomy System in United States

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced the launch of the Auryon Atherectomy System, a newly-developed innovative technology for the treatment of Peripheral Artery Disease (PAD),including Critical Limb Ischemia (CLI) and In-Stent Restenosis (ISR).

Sep 17, 2020 04:01 pm ET

AngioDynamics to Report Fiscal 2021 First Quarter Financial Results on September 29, 2020

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of fiscal year 2021 before the market open on Tuesday, September 29, 2020. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Aug 17, 2020 08:00 am ET

AngioDynamics Announces First Patient Enrolled in PATHFINDER I Registry Examining Long-Term Effectiveness and Safety of Auryon Atherectomy System

Aug 03, 2020 04:01 pm ET

AngioDynamics to Participate in a Virtual Fireside Chat at the Canaccord Genuity Growth Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will participate in a virtual fireside chat at the 40th Annual Canaccord Genuity Growth Conference at 1:30 p.m. ET on Wednesday, August 12, 2020.

Jul 16, 2020 07:00 am ET

AngioDynamics Reports Fiscal 2020 Fourth Quarter and Full-Year Financial Results

Jun 23, 2020 04:01 pm ET

AngioDynamics to Report Fiscal 2020 Fourth Quarter and Full-Year Financial Results on July 16, 2020

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the fourth quarter and fiscal year 2020 before the market open on Thursday, July 16, 2020. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Jun 08, 2020 04:01 pm ET

AngioDynamics to Participate in a Virtual Fireside Chat at the Raymond James Human Health Innovation Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the Raymond James Human Health Innovation Conference at 12:20 p.m. ET on Thursday, June 18, 2020.

May 07, 2020 04:01 pm ET

AngioDynamics to Present at the UBS Virtual Global Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the UBS Virtual Global Healthcare Conference at 9:10 a.m. ET on Monday, May 18, 2020.

Apr 07, 2020 07:00 am ET

AngioDynamics Reports Fiscal 2020 Third Quarter Financial Results

Mar 10, 2020 04:01 pm ET

AngioDynamics to Report Fiscal 2020 Third Quarter Financial Results on April 7, 2020

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the third quarter of fiscal year 2020 before the market open on Tuesday, April 7, 2020. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Feb 27, 2020 04:01 pm ET

AngioDynamics to Present at Two Investor Conferences in March

Feb 06, 2020 08:00 am ET

AngioDynamics Appoints Stephen Trowbridge Executive Vice President and Chief Financial Officer

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has appointed Stephen Trowbridge to the role of Executive Vice President and Chief Financial Officer, effective February 5, 2020.

Jan 16, 2020 11:00 am ET

AngioDynamics Launches PATHFINDER I Registry to Evaluate Performance and Clinical Outcomes of the AURYON™ Atherectomy System

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced the launch of the PATHFINDER I: Post-Market Registry (PATHFINDER I-Registry, EX-PAD-05), a pilot study to evaluate the safety and efficacy of the Company’s AURYON Atherectomy System in the treatment of de novo, re-stenotic, and in-stent restenosis (ISR) lesions in infrainguinal arteries of patients with Peripheral Artery Diseases (PAD).

Jan 07, 2020 07:00 am ET

AngioDynamics Reports Fiscal 2020 Second Quarter Financial Results

Jan 06, 2020 08:00 am ET

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Sr. Vice President, General Counsel, and Interim Chief Financial Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference at 8:00 a.m. PT on Thursday, January 16, 2020 in San Francisco, CA.

Dec 10, 2019 04:01 pm ET

AngioDynamics to Report Fiscal 2020 Second Quarter Financial Results on January 7, 2020

To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and refer to the passcode 13697417.

Oct 22, 2019 04:01 pm ET

AngioDynamics Announces Departure of CFO and Appointment of Interim CFO

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Michael C. Greiner, Executive Vice President and Chief Financial Officer (CFO) will be departing the Company. Stephen A. Trowbridge, Senior Vice President and General Counsel, will assume the role of interim Chief Financial Officer in addition to his current responsibilities.

Oct 03, 2019 06:02 am ET

AngioDynamics Reports Fiscal 2020 First Quarter Financial Results

Oct 03, 2019 06:00 am ET

AngioDynamics Acquires Eximo Medical, Ltd. and its Innovative 355nm Laser Atherectomy Technology

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has acquired Eximo Medical, Ltd., an early commercial stage, medical device company, and its proprietary 355nm wavelength laser-technology platform for $46 million in up-front consideration with up to $20 million of contingent consideration related to certain technical and revenue milestones. The transaction is being funded exclusively through the use of cash on hand.

Sep 09, 2019 08:00 am ET

AngioDynamics Awarded Premier’s Nationally Outsourced Implantable Infusion Port Agreement

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the Company has been awarded a dual-source group purchasing agreement by Premier, Inc. to supply implantable infusion ports. The three-year agreement becomes effective on November 1, 2019 and allows Premier Members to take advantage of pre-negotiated pricing and terms for AngioDynamics’ Smart Port®, BioFlo®, Vortex®, and Xcela® port technologies.

Sep 05, 2019 04:01 pm ET

AngioDynamics to Report Fiscal 2020 First Quarter Financial Results on October 3, 2019

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of fiscal year 2020 before the market open on Thursday, October 3, 2019. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Jul 31, 2019 04:01 pm ET

AngioDynamics Announces Appointment of Former Johnson & Johnson Executive Karen Licitra to its Board of Directors

Jul 23, 2019 04:01 pm ET

AngioDynamics to Present at the Canaccord Genuity Growth Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will present at the 39th Annual Canaccord Genuity Growth Conference at 10:30 a.m. ET on Wednesday, August 7, 2019 in Boston, MA.

Jul 10, 2019 07:00 am ET

AngioDynamics Reports Fiscal 2019 Fourth Quarter and Full-Year Financial Results

Jun 20, 2019 04:01 pm ET

AngioDynamics to Report Fiscal 2019 Fourth Quarter and Full-Year Financial Results on July 10, 2019

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the fourth quarter and fiscal year 2019 before the market open on Wednesday, July 10, 2019. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Jun 04, 2019 04:01 pm ET

AngioDynamics to Present at the Raymond James Life Sciences and MedTech Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will present at the Raymond James Life Sciences and MedTech Conference at 1:50 p.m. ET on Tuesday, June 18, 2019 in New York, NY.

Jun 03, 2019 04:01 pm ET

AngioDynamics Completes Sale of NAMIC® Fluid Management Portfolio to Medline Industries, Inc.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it closed the previously announced sale of its NAMIC® fluid management portfolio to Medline Industries, Inc. on May 31, 2019 for $167.5 million.

May 28, 2019 08:00 am ET

AngioDynamics to Ring NASDAQ Closing Bell to Celebrate the 15th Anniversary of its Listing on the Exchange

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that representatives of the Company will ring the NASDAQ Stock Market closing bell on Tuesday, May 28, 2019 at 4:00 p.m. ET to commemorate the 15-year anniversary of the Company’s listing on the exchange.

May 22, 2019 08:00 am ET

AngioDynamics Receives FDA Approval to Initiate Pilot Study for the Use of NanoKnife® to Treat Prostate Cancer

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the United States Food and Drug Administration (FDA) approved the Company’s investigational device exemption (IDE) application for its NanoKnife® Irreversible Electroporation pilot study for the ablation of prostate cancer tissue in low-risk patients.

May 13, 2019 08:00 am ET

AngioDynamics Announces First Patient Enrolled in NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced enrollment of the first patient in its NanoKnife® Irreversible Electroporation (IRE) “Data IRE Cancer Treatment” clinical study (DIRECT).

Apr 17, 2019 04:05 pm ET

AngioDynamics Announces Agreement to Sell NAMIC® Fluid Management Business to Medline Industries, Inc. for $167.5 Million

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for oncology, vascular access, and peripheral vascular disease, today announced that it has entered into a definitive agreement to sell its NAMIC® fluid management portfolio to Medline Industries, Inc. for $167.5 million, subject to customary closing conditions including antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Apr 17, 2019 08:01 am ET

AngioDynamics’ DIRECT Clinical Study Receives Institutional Review Board Approval for the Treatment of Stage III Pancreatic Cancer

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the Company received central Institutional Review Board (IRB) approval to conduct its NanoKnife® Irreversible Electroporation “Direct IRE Cancer Treatment” clinical study (DIRECT). The IRB approval closely f

Apr 05, 2019 02:00 am ET

Report: Developing Opportunities within 22nd Century Group, Darling Ingredients, Silvercorp Metals, Trevena, Star Bulk Carriers, and AngioDynamics — Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of 22nd Century Group, Inc (NYSE:XXII), Darling Ingredients Inc. (NYSE:DAR),...

Apr 02, 2019 07:00 am ET

AngioDynamics Reports Fiscal 2019 Third Quarter Financial Results

Apr 01, 2019 04:01 pm ET

AngioDynamics to Present at the Needham Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Michael C. Greiner, Executive Vice President and Chief Financial Officer, will present at the 18th Annual Needham Healthcare Conference at 1:30 p.m. ET on Tuesday, April 9, 2019 in New York, NY.

Apr 01, 2019 06:00 am ET

AngioDynamics Receives FDA Approval to Initiate NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States Food and Drug Administration (FDA) approved the Company’s investigational device exemption (IDE) application for its NanoKnife® Irreversible Electroporation “Direct IRE Cancer Treatment” cli

Mar 28, 2019 06:48 pm ET

CORRECTING and REPLACING OARtrac® Radiation Dose Monitoring System Receives Expanded FDA Clearance for Electron Radiation Therapy

Second paragraph, first sentence of release should read: The additional indications clear the OARtrac System for use with patient-specific, pre-calibrated Plastic Scintillating Detector (PSD) sensors used during cancer treatments to measure photon and electron radiation therapy as an adjunct to treatment planning (instead of: The additional indications clear the OARtrac System for use with patient-specific, pre-calibrated peak skin dose (PSD) sensors used during cancer treatments to measure photon and electron radiation therapy as an adjunct to

Mar 12, 2019 04:01 pm ET

AngioDynamics to Report Fiscal 2019 Third Quarter Financial Results on April 2, 2019

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the third quarter of fiscal year 2019 before the market open on Tuesday, April 2, 2019. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Mar 08, 2019 01:01 pm ET

AngioDynamics Wins Patent Infringement Dispute With Bard

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States District Court for the District of Delaware, on day four of a jury trial at the close of C.R. Bard’s case (Plaintiff), granted judgement as a matter of law under rule 50(a) in favor of AngioDynamics, dismissing Bard’s suit alleging that certain of AngioDynamics’ implantable port products infringed three Bard patents.

Feb 26, 2019 04:01 pm ET

AngioDynamics to Present at the Barclays Global Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Michael C. Greiner, Executive Vice President and Chief Financial Officer, will present at the Barclays Global Healthcare Conference at 4:20 p.m. ET on Wednesday, March 13, 2019 in Miami Beach, FL.

Jan 30, 2019 07:35 am ET

New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis — Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Heron Therapeutics, Inc. (NASDAQ:HRTX), IDACORP, Inc. (NYSE:IDA), Star...

Jan 04, 2019 07:00 am ET

AngioDynamics Reports Fiscal 2019 Second Quarter Financial Results

Dec 20, 2018 04:01 pm ET

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Michael C. Greiner, Executive Vice President and Chief Financial Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Tuesday, January 8, 2019 in San Francisco, CA.

Dec 10, 2018 04:01 pm ET

AngioDynamics to Report Fiscal 2019 Second Quarter Financial Results on January 4, 2019

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the second quarter of fiscal year 2019 before the market open on Friday, January 4, 2019. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Oct 16, 2018 08:40 am ET

Consolidated Research: 2018 Summary Expectations for Mimecast, Shiloh Industries, Adverum Biotechnologies, AngioDynamics, Kimball Electronics, and Changyou — Fundamental Analysis, Key Performance Indi

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Mimecast Limited (NASDAQ:MIME), Shiloh Industries, Inc. (NASDAQ:SHLO),...

Sep 27, 2018 07:00 am ET

AngioDynamics Reports Fiscal 2019 First Quarter Financial Results

Sep 19, 2018 04:01 pm ET

AngioDynamics to Present at the Cantor Global Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Michael C. Greiner, Executive Vice President and Chief Financial Officer, will present at the Cantor Global Healthcare Conference at 8:35 a.m. ET on Tuesday, October 2, 2018 in New York, NY.

Sep 13, 2018 04:01 pm ET

AngioDynamics to Report Fiscal 2019 First Quarter Financial Results on September 27, 2018

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of fiscal year 2019 before the market open on Thursday, September 27, 2018. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Sep 13, 2018 07:00 am ET

AngioDynamics to Acquire RadiaDyne and its Revolutionary OARtrac® Radiation Dose Monitoring Platform to Further Expand Oncology Portfolio

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes.

Aug 23, 2018 04:01 pm ET

AngioDynamics to Present at Two Investor Conferences in September

Aug 17, 2018 07:55 am ET

Factors of Influence in 2018, Key Indicators and Opportunity within Okta, Great Lakes Dredge & Dock, MDC Partners, Colfax, Heritage-Crystal Clean, and AngioDynamics — New Research Emphasizes Economic

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Okta, Inc. (NASDAQ:OKTA), Great Lakes Dredge Dock Corporation...

Aug 15, 2018 07:00 am ET

AngioDynamics Provides Updates on Oncology and Vascular Access Businesses

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today provided a corporate update on enhancements made to its Oncology business and acknowledged a recent, favorable U.S. District Court ruling that impacts its Vascular Access business.

Jul 11, 2018 07:00 am ET

AngioDynamics Reports Fiscal 2018 Fourth Quarter and Full-Year Financial Results

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, oncology and surgery, today announced financial results for the fourth quarter and fiscal year, which ended May 31, 2018.

Jun 21, 2018 04:01 pm ET

AngioDynamics to Report Fiscal 2018 Fourth Quarter and Full-Year Financial Results on July 11, 2018

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that it will report financial results for the fourth quarter and fiscal year 2018 before the market open on Wednesday, July 11, 2018. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

May 29, 2018 08:15 am ET

Research Report Identifies AngioDynamics, Kaiser Aluminum, Mammoth Energy Services, Meridian Bioscience, Merrimack Pharmaceuticals, and Energizer with Renewed Outlook — Fundamental Analysis, Calculati

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AngioDynamics, Inc. (NASDAQ:ANGO), Kaiser Aluminum Corporation...

Apr 10, 2018 04:01 pm ET

AngioDynamics to Present at Two Investor Conferences in May

Apr 04, 2018 08:20 am ET

Recent Analysis Shows Multi-Color, Madrigal Pharmaceuticals, SPX, AngioDynamics, Atara Biotherapeutics, and Quanex Building Products Market Influences — Renewed Outlook, Key Drivers of Growth

NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Multi-Color Corporation (NASDAQ:LABL), Madrigal Pharmaceuticals, Inc....

Mar 29, 2018 07:00 am ET

AngioDynamics Reports Fiscal 2018 Third Quarter Financial Results

Mar 15, 2018 04:01 pm ET

AngioDynamics to Present at the Needham 17th Annual Healthcare Conference

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that Michael C. Greiner, Executive Vice President and Chief Financial Officer, will present at the Needham 17th Annual Healthcare Conference at 4:00 p.m. ET on Tuesday, March 27, 2018 in New York, NY.

Feb 27, 2018 04:01 pm ET

AngioDynamics to Report Fiscal 2018 Third Quarter Financial Results on March 29, 2018

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that it will report financial results for the third quarter of fiscal year 2018 before the market open on Thursday, March 29, 2018. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Feb 15, 2018 08:00 am ET

AngioDynamics to Present at the Barclays Global Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Michael C. Greiner, Executive Vice President and Chief Financial Officer, will present at the Barclays Global Healthcare Conference at 3:20 p.m. ET on Tuesday, March 13, 2018 in Miami Beach, FL.

Feb 06, 2018 08:00 am ET

Investor Expectations to Drive Momentum within Regal Beloit, Kaiser Aluminum, AngioDynamics, Mulesoft, Assembly Biosciences, and Woodward — Discovering Underlying Factors of Influence

NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Regal Beloit Corporation (NYSE:RBC), Kaiser Aluminum...

Jan 24, 2018 04:01 pm ET

AngioDynamics Receives FDA Expedited Access Pathway Designation for the NanoKnife® System for the Treatment of Stage III Pancreatic Cancer

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that the United States Food and Drug Administration (FDA) has granted the Expedited Access Pathway (EAP) designation to the Company’s NanoKnife® System and proposed indication for use for the treatment of Stage III pancreatic cancer.

Jan 04, 2018 07:00 am ET

AngioDynamics Reports Fiscal 2018 Second Quarter Financial Results

Dec 19, 2017 04:01 pm ET

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Michael C. Greiner, Executive Vice President and Chief Financial Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference at 3:30 p.m. PT on Wednesday, January 10, 2018 in San Francisco, CA.

Dec 11, 2017 04:01 pm ET

AngioDynamics to Report Fiscal 2018 Second Quarter Financial Results on January 4, 2018

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that it will report financial results for the second quarter of fiscal year 2018 before the market open on Thursday, January 4, 2018. The Company’s management will host a conference call at 8:00 a.m. ET that same day to discuss the results.

Aug 07, 2017 07:48 am ET

AngioDynamics to Present at the 2017 Canaccord Genuity Growth Conference

ALBANY, N.Y., Aug. 07, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Michael Greiner, Executive Vice President and Chief Financial Officer, is scheduled to present and participate in a fireside chat at the Canaccord Genuity Growth Conference on Thursday, August 10, 2017, at 11:00 a.m. ET. The conference will be held at the InterContinental in Boston, MA....

Jul 26, 2017 10:19 am ET

INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of AngioDynamics, Inc. - ANGO

NEW YORK, July 25, 2017 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City announces it is investigating AngioDynamics, Inc. (NasdaqGS: ANGO)("AngioDynamics" or the "Company") for possible violations of federal securities laws.

Jul 24, 2017 02:21 pm ET

Lifshitz & Miller LLP Announces Investigation of Acacia Communications, Inc., AngioDynamics, Inc., ClubCorp Holdings, Inc., HD Supply Holdings, Inc., Ocular Therapeutix, Inc., Repros Therapeutics Inc

NEW YORK, July 24, 2017 /PRNewswire/ --

Jul 18, 2017 03:32 pm ET

ANGIODYNAMICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In AngioDynamics, Inc. To Contact The Firm

NEW YORK, July 18, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at AngioDynamics, Inc. ("AngioDynamics" or the "Company") (NASDAQ: ANGO).

Jul 18, 2017 03:11 pm ET

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AngioDynamics, Inc. (ANGO)

NEW YORK, July 18, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AngioDynamics, Inc. ("AngioDynamics" or the "Company") (NASDAQ: ANGO). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/ango.

Jul 18, 2017 01:00 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AngioDynamics, Inc. - ANGO

NEW YORK, July 18, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AngioDynamics, Inc. ("AngioDynamics" or the "Company") (NASDAQ: ANGO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.

Jan 09, 2017 09:51 am ET

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating AngioDynamics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

NEW YORK, Jan. 9, 2017 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of AngioDynamics, Inc. (NASDAQ: ANGO).

Nov 14, 2016 07:52 pm ET

AngioDynamics Announces Pricing of Secondary Offering by Selling Stockholders

ALBANY, N.Y., Nov. 14, 2016 (GLOBE NEWSWIRE) -- AngioDynamics, Inc. (NASDAQ:ANGO) (the “Company”), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the pricing of the previously announced underwritten public offering by certain of its stockholders (the “Selling Stockholders”) of 2,500,000 shares of common stock at a price to the public of $16.00 per share. The Company has agreed to repurchase from the underwriter 500,000 shares of the 2,500,000 shares of common stock being sold by th...

Nov 14, 2016 04:08 pm ET

AngioDynamics Announces Secondary Offering of 2,500,000 Shares of Common Stock by Selling Stockholders

ALBANY, N.Y., Nov. 14, 2016 (GLOBE NEWSWIRE) -- AngioDynamics, Inc. (NASDAQ:ANGO) (the “Company”), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that certain of its stockholders (the “Selling Stockholders”) intend to offer for sale in an underwritten secondary offering 2,500,000 shares of common stock pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission (the “SEC”), of which the Company intends to repurchase from the underwriter ...

Oct 05, 2016 06:00 am ET

AngioDynamics Reports Fiscal 2017 First Quarter Results

Q1 net sales of $88.1 million, up 5% year-over-yearQ1 GAAP earnings per share of $0.04; non-GAAP adjusted EPS of $0.17Q1 operating cash generation of $7.4 millionFY2017 guidance remains unchanged ALBANY, N.Y., Oct. 05, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today reported first quarter financial results for the 2017 fiscal quarter ended August 31, 2016....

Sep 21, 2016 06:00 am ET

AngioDynamics to Report Fiscal 2017 First Quarter Financial Results

ALBANY, N.Y., Sept. 21, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2017 first quarter ended August 31, 2016, on Wednesday, October 5, 2016, before the open of the U.S. financial markets....

Sep 19, 2016 08:02 am ET

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating AngioDynamics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

NEW YORK, Sept. 19, 2016 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of AngioDynamics, Inc. (NASDAQ: ANGO).

Sep 06, 2016 08:37 am ET

AngioDynamics to Present at the 2016 Morgan Stanley Global Healthcare Conference

ALBANY, N.Y., Sept. 06, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Jim Clemmer, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 2016 Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016, at 2:55 p.m. EST. The conference will be held at the Grand Hyatt in New York City....

Aug 08, 2016 02:30 pm ET

AngioDynamics to Present at the 2016 Canaccord Genuity Growth Conference

ALBANY, N.Y., Aug. 08, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Jim Clemmer, President and Chief Executive Officer, is scheduled to present at the 2016 Canaccord Genuity Growth Conference on Wednesday, August 10, 2016, at 4:30 p.m. ET. The conference will be held at the InterContinental in Boston, Mass....

Aug 01, 2016 04:30 pm ET

AngioDynamics Announces Secondary Offering of 2,250,000 Shares of Common Stock by Selling Stockholders

ALBANY, N.Y., Aug. 01, 2016 (GLOBE NEWSWIRE) -- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that Avista Capital Partners, LP and affiliated investment funds intend to offer for sale 2,250,000 shares of common stock in an underwritten secondary offering, pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission (“SEC”). The selling shareholders will receive all of the net proceeds from the offering....

Jul 25, 2016 07:34 am ET

AngioDynamics Appoints Michael C. Greiner as New Chief Financial Officer

ALBANY, N.Y., July 25, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of Michael Greiner as the company’s new Executive Vice President and Chief Financial Officer, effective August 16, 2016....

Jul 13, 2016 06:00 am ET

AngioDynamics Reports Fiscal 2016 Fourth Quarter and Full Year Results

Q4 Net sales of $93.4 million, up 3% year-over-yearQ4 GAAP loss per share of $1.21, inclusive of a one-time tax asset write down of $40.1 million; Non-GAAP adjusted EPS of $0.19, up 37% year-over-yearQ4 Operating cash generation of $18.5 millionFY2017 revenue guidance set at $355-$360 million, adjusted EPS of $0.62-$0.65 ...

Jun 29, 2016 06:00 am ET

AngioDynamics to Report Fiscal 2016 Fourth Quarter and Full Year Financial Results

ALBANY, N.Y., June 29, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2016 fourth quarter and full year ended May 31, 2016, on Wednesday, July 13, 2016, before the open of the U.S. financial markets....

Apr 28, 2016 12:08 pm ET

PAVmed Inc. (Nasdaq: PAVMU) to Ring The Nasdaq Stock Market Opening Bell

ADVISORY, April 28, 2016 (GLOBE NEWSWIRE) -- ...

You are here

AngioDynamics, Inc. (OQ:ANGO)

Business Focus: Medical Equipment, Supplies & Distribution